Dr. Hiroshi Zimmermann

Radiation oncologist · Gustave Roussy · France (FR) · Oncology

Tier 1STK-0018GoodOwner MSL RARachel Adeyemi

Data minimisation

Consent status: Recorded. The name shown may be a pseudonym. Contact details, personal identifiers and remuneration fields are hidden for your role; only scientific-profile fields needed for engagement planning are displayed.

Specialty: Thoracic oncology
Disease interests: NSCLC
Scientific interests: Elderly patients
Engagement preference: Either
Advisory boards: 2
Publications: 98
Source system: Veeva CRM
Data quality: Good

Engagement plan

Cadence target for Tier 1: 4 per year (assumption)

Last engaged: 21 Mar 2026 (178 days ago)
Next planned contact: 20 Jun 2026 Overdue
Last 6 months vs target: 50%
1 of 2 expected engagements

Insights from this stakeholder (1)

INS-0024PD-L1 testing turnaround
23 Mar 2026 · Competitor activity
MediumDeduplicated

Engagement history (1)

All engagements including drafts, newest first

Date	Type	Format	MSL	Product	Topics	Insights	Flags	Status
21 Mar 2026	Congress meeting	In person	Rachel Adeyemi	Vantrexa	PD-L1 testing turnaround	1	—	Reviewed	ENG-0062

Timeline

21 Mar 2026
Congress meeting
PD-L1 testing turnaround

Related stakeholders (5)

Gustave Roussy

Dr. William Ivanova
Radiation oncologist
Tier 1
Dr. Chloé Xu
Oncology pharmacist
Tier 2
Dr. Ulrich Kimura
Oncology pharmacist
Tier 1
Dr. Yuki Castellano
Academic nephrologist
Tier 3
Dr. Javier Kimura
Renal pathologist
Tier 3